American Regent v. Eugia Pharma: Selenious Acid Patent Consolidated into 13-Defendant ANDA Battle
American Regent, Inc. filed suit against Eugia Pharma Specialities Ltd. and Eugia US LLC in the District of New Jersey, asserting US11998565B2 over its selenious acid injectable products. Within 77 days the case was consolidated with 12 parallel actions against generic manufacturers, making this one of the broadest simultaneous ANDA enforcement campaigns in recent injectable pharma litigation.
A 13-front ANDA war over injectable selenium — consolidated fast
American Regent, Inc., a specialty injectable pharmaceutical company, filed Civil Action No. 2:24-cv-08956 on 5 September 2024 in the U.S. District Court for the District of New Jersey against Eugia Pharma Specialities Ltd. and its U.S. affiliate Eugia US LLC. The suit asserts US11998565B2, a patent covering ARI’s selenious acid injectable products, in response to what is consistent with an ANDA filing by Eugia seeking FDA approval to market a generic version of those products.
On 22 October 2024, all parties jointly moved to consolidate this action with twelve substantially identical suits ARI had filed against competing generic applicants — including Accord Healthcare, Cipla, Dr. Reddy’s, Hikma, Sun Pharma, and eight others — all before the same judge. The court granted consolidation, terminating this docket and directing that all filings be maintained under lead case No. 2:24-cv-7791. No merits ruling, claim construction, or injunction was issued in this matter.
The 77-day runway from filing to consolidation is notably brief and suggests the parties moved efficiently to streamline what would otherwise be over a dozen parallel discovery tracks. The public record does not disclose whether any 30-month stay has been triggered, what claim terms are in dispute, or the status of negotiations with any individual defendant. The substantive battle — including infringement and validity contests — now proceeds in the consolidated lead action.
Filing to Case Consolidated in 77 days
77 days — rapid consolidation, well below average ANDA case lifespan
What case consolidation means for the Eugia action and what comes next
Consolidation ends this docket — the dispute lives on
Under Federal Rule of Civil Procedure 42(a), a district court may consolidate actions sharing common questions of law or fact. Here, all 13 cases turn on the same patent (US11998565B2) and the same product category. Consolidation does not dismiss or resolve any claim — it merges the proceedings into one docket for efficiency. Eugia remains a named defendant in the consolidated action.
No merits rulingARI retains all claims against Eugia in consolidated action
American Regent’s infringement claims against Eugia are fully preserved in the lead case No. 2:24-cv-7791. Consolidation typically benefits a plaintiff holding a single patent against multiple generic filers — it avoids inconsistent claim constructions and reduces duplicative litigation costs. ARI now litigates one coordinated campaign rather than 13 separate tracks.
Claims fully preservedEugia litigates alongside 12 rival generic applicants
Consolidation means Eugia shares discovery, briefing schedules, and likely claim construction proceedings with a dozen competing generic manufacturers. This can dilute individual leverage in settlement negotiations but may also allow cost-sharing on validity challenges. Eugia has not conceded infringement or validity — those questions remain entirely open before the New Jersey court.
Validity contest remains openBroad enforcement signals ARI is defending selenious acid market aggressively
The simultaneous filing against 13 generic applicants — spanning major Indian and U.S. manufacturers — is consistent with a coordinated Paragraph IV ANDA defence strategy. A 30-month stay, if triggered, would block FDA approval of any listed generic pending resolution. Companies in the injectable micronutrient or parenteral nutrition space should monitor the consolidated docket for claim construction rulings that may define the patent’s scope.
Watch lead case 24-7791Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | American Regent, Inc. | Company | Specialty injectable pharma company — holder of US11998565B2Search in Eureka ↗ |
| Defendant | Eugia Pharma Specialities, Ltd. | Company | Indian generic pharmaceutical manufacturer and its U.S. distribution entitySearch in Eureka ↗ |
| Co-Defendant | Eugia US LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Charles H. Chevalier | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Christine A. Gaddis | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Dennies Varughese | Attorney | Counsel for American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Sterne Kessler Goldstein & Fox | Law Firm | Representing American Regent, Inc.Search in Eureka ↗ |
| Defendant counsel | Dmitry V. Shelhoff | Attorney | Counsel for Eugia Pharma Specialities, Ltd.Search in Eureka ↗ |
| Defendant counsel | KENNETH CANFIELD | Attorney | Counsel for Eugia Pharma Specialities, Ltd.Search in Eureka ↗ |
| Defendant counsel | STUART D. SENDER | Attorney | Counsel for Eugia Pharma Specialities, Ltd.Search in Eureka ↗ |
| Defendant law firm | Pergament & Cepeda LLP | Law Firm | Representing Eugia Pharma Specialities, Ltd.Search in Eureka ↗ |
| Defendant law firm | Windels Marx Lane & Mittendorf, LLP | Law Firm | Representing Eugia Pharma Specialities, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order does not adjudicate infringement or validity — it is a procedural instrument directing all 13 actions to proceed under a single docket. The verbatim recitation of each co-defendant action in the order confirms that Eugia’s case is substantively identical in subject matter to the parallel suits. No claim terms have been construed, no preliminary injunction issued, and no liability determined. The substantive merits of ARI’s infringement assertions against Eugia remain entirely at issue in the consolidated proceeding.
US11998565B2 — Selenious Acid Injectable Pharmaceutical Formulation
US11998565B2, filed under application number US18/124391, covers ARI’s selenious acid products — pharmaceutical formulations used in parenteral nutrition to deliver selenium intravenously. Selenium is an essential trace element, and injectable selenious acid is administered to patients who cannot receive adequate nutrition orally, including critically ill and oncology patients. The patent’s grant and assertion against thirteen ANDA filers simultaneously suggests ARI views its claims as broadly covering the commercially relevant formulation space.
For the injectable pharmaceutical sector, this patent represents a significant exclusivity position over a niche but clinically important product. Selenious acid injectables compete in a market served almost entirely by generic manufacturers, making US11998565B2 a commercial barrier of considerable weight. The breadth of enforcement — spanning Indian multinationals such as Dr. Reddy’s, Sun Pharma, and Cipla alongside U.S. specialists — indicates ARI considers its patent coverage wide enough to block most viable generic formulation approaches currently under ANDA review.
Should your team run an FTO analysis against US11998565B2?
Any company developing, manufacturing, or seeking FDA approval for a selenious acid injectable product — or any parenteral selenium formulation — should treat US11998565B2 as a primary FTO risk. The patent is actively enforced and the consolidated New Jersey litigation signals ARI will pursue all ANDA filers. R&D and regulatory teams at generic manufacturers, contract development organisations, and parenteral nutrition suppliers are directly in scope.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US11998565B2 against your formulation parameters, identify prior art that may support IPR or inter partes review arguments, and flag related continuation or family applications that could extend exclusivity. Run an automated FTO report to understand design-around viability before committing to an ANDA filing or product development programme targeting this therapeutic category.
Run a freedom-to-operate analysis on US11998565B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA Patent Cases: Injectable Pharma in the District of New Jersey
Cases involving Paragraph IV ANDA challenges to injectable pharmaceutical patents litigated in the District of New Jersey, including multi-defendant consolidations.
What this case signals for the injectable pharma IP landscape
A 13-defendant ANDA consolidation over a single injectable patent is a calibrated enforcement posture — here is what it means.
Simultaneous multi-defendant ANDA suits are a deliberate prosecution strategy
Filing against all ANDA applicants on the same day preserves the 30-month stay for each filer and prevents any single generic from gaining a first-mover advantage. IP teams in injectable pharma should note this pattern as a benchmark for coordinated Hatch-Waxman enforcement.
Consolidation accelerates claim construction — and crystallises risk for all defendants
A single Markman hearing in the consolidated case will bind all 13 defendants simultaneously. Any adverse claim construction ruling cannot be relitigated by individual defendants. Generic applicants facing a consolidated ANDA docket should invest early in unified invalidity strategy before the Markman stage.
American v Eugia — key questions answered
The case was consolidated with 12 parallel actions under lead docket No. 2:24-cv-7791. American Regent filed suit against Eugia Pharma Specialities Ltd. and Eugia US LLC on 5 September 2024 asserting US11998565B2 over its selenious acid injectable products. No merits ruling was issued; the case terminated by consolidation on 21 November 2024.
American Regent asserts US11998565B2, filed under application US18/124391, which covers its selenious acid injectable pharmaceutical products used in parenteral nutrition. The same patent is asserted in all 13 consolidated actions filed against generic ANDA applicants in the District of New Jersey.
Consolidation under Rule 42(a) means Eugia’s case is merged into lead docket No. 2:24-cv-7791. All claims against Eugia are preserved — no dismissal occurred. Eugia will share discovery and likely a single Markman claim construction hearing with 12 co-defendants, all of whom are alleged to infringe US11998565B2.
American Regent filed 13 separate actions against generic pharmaceutical manufacturers, including Eugia, Accord Healthcare, Aspiro Pharma, Cipla, Dr. Reddy’s Laboratories, Gland Pharma, Hikma, Long Grove Pharmaceuticals, RK Pharma, Somerset Therapeutics, Sun Pharmaceutical, Xiromed, and Zydus. All were consolidated into lead case No. 2:24-cv-7791.
The public record in this case does not expressly confirm whether a 30-month stay under the Hatch-Waxman Act has been triggered, but the filing of a timely patent infringement action following an ANDA Paragraph IV certification is typically sufficient to invoke the automatic stay. Stakeholders should monitor the consolidated docket and FDA Orange Book listings for confirmation.
PatSnap Eureka searches patents and litigation data to answer instantly.